Optellum

Focus: Optellum is a UK-based biotechnology company specializing in artificial intelligence and diagnostic solutions for lung health, with a focus on early lung cancer detection through AI-powered pulmonary nodule analysis.

Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Optellum

AI assessmentNot Hiring

No open roles listed right now. Follow Optellum to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SCOOT: Sample Collection for DART

Lung Cancer

N/A

IDEAL: Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis Study

Pulmonary Nodule, Solitary

N/A

Clinical Trials (1)

Help build intelligence for Optellum

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work at the intersection of AI/machine learning and clinical diagnostics in a high-unmet-need area (early lung cancer detection)
Oxford-based biotech offers proximity to world-class academic research infrastructure and collaborative partnerships
Early-stage company provides potential for meaningful impact on product development and strategic direction

Watch Out For

Pre-revenue stage with unknown funding and financial runway creates uncertainty around long-term stability and compensation competitiveness
Currently zero open job positions signals potential hiring freeze or limited growth capacity
Minimal published clinical data (2 trials, both non-Phase studies) means product validation and market traction remain unproven

Generated by Claude from Optellum's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.